Loncastuximab tesirine

STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral presentations. These feature the most recent clinical data and insights from completed and ongoing studies across Sobi's innovative portfolio including data from efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib. These presentations underscore Sobi's mission to deliver life-changing therapies for patients with rare and severe blood disorders. "We will present evidence at ASH from a post hoc analysis demonstrating that pacritinib reduces or stabilises spleen size, improves haematologic parameters, and lessens myelofibrosis symptoms in patients with highrisk disease. These findings matter because they address key drivers of morbidity which affect daytoday functioning and quality of life. The ASH meeting also offers an opportunity to discuss the latest research on emapalumab, efanesoctocog alfa, pegcetacoplan, avatrombopag, as well as loncastuximab tesirine," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. Summary of full Sobi data to be presented at ASH 2025: Overview of treatment advances with complement Inhibitors in patients with Paroxysmal Nocturnal Haemoglobinuria. Optimising PNH treatment with the complement inhibitor Pegcetacoplan: A case report. User experience with Pegcetacoplan on-body Injector in patients with Paroxysmal Nocturnal Hemoglobinuria. About ALTUVOCT ® (efanesoctocog alfa) ALTUVOCT ® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity. About the Sobi and Sanofi Collaboration Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Aspaveli®/Empaveli® (pegcetacoplan) Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the United States. It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally. About the Sobi and Apellis Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Doptelet® (avatrombopag) Doptelet (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. Doptelet is also approved for the treatment of chronic ITP in pediatric patients. About Gamifant® (emapalumab-lzsg) Gamifant is an anti-IFNγ antibody that binds free and receptor-bound IFNγ, which when secreted in an uncontrolled manner can cause hyperinflammation. Gamifant is indicated for intravenous infusion over one hour and is FDA approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) in Still's disease. About Vonjo® (pacritinib) Vonjo (pacritinib) is a kinase inhibitor indicated in the United States for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Vonjo is also being investigated for other rare hematologic conditions, including VEXAS syndrome. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

Press releases News Image gallery YouTube Subscribe Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year’s meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral presentations. These feature the most recent clinical data and insights from completed and ongoing studies across Sobi’s innovative portfolio including data from efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib. These presentations underscore Sobi’s mission to deliver life-changing therapies for patients with rare and severe blood disorders. “We will present evidence at ASH from a post hoc analysis demonstrating that pacritinib reduces or stabilises spleen size, improves haematologic parameters, and lessens myelofibrosis symptoms in patients with highrisk disease. These findings matter because they address key drivers of morbidity which affect daytoday functioning and quality of life. The ASH meeting also offers an opportunity to discuss the latest research on emapalumab, efanesoctocog alfa, pegcetacoplan, avatrombopag, as well as loncastuximab tesirine,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. Summary of full Sobi data to be presented at ASH 2025: Efanesoctocog alfa Clinical outcomes up to four years of once-weekly Efanesoctocog Alfa Prophylaxis in previously treated adults, adolescents, and children with severe Haemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study. Oral Presentation Session Name: 322. Haemophilia A and B: Clinical and epidemiological: Innovations shaping the future of Haemophilia care Date: 7 December 2025 Time: 12:00 PM - 1:30 PM ET Presentation Time: 1:00 PM - 1:15 PM ET Room: OCCC – W304EFGH Publication Number: 539 Understanding unmet needs for people with Haemophilia A receiving factor and non-factor treatments. Poster Presentation Session Name: Poster Session I Date: 6 December 2025 Time: 5:30 PM - 7:30 PM ET Room: OCCC - West Halls B3-B4 Publication Number: 2679 Real-world experience of Efanesoctocog Alfa in Haemophilia A patients in the US: A retrospective analysis. Poster Presentation Session Name: Poster Session I Date: 6 December 2025 Time: 5:30 PM - 7:30 PM ET Room: OCCC - West Halls B3-B4 Publication Number: 1286 Patient characteristics, treatment patterns, and bleeding in people with Haemophilia A without inhibitors initiating Efanesoctocog alfa in the US: An administrative claims analysis. Poster Presentation Session Name: Poster Session I Date: 6 December 2025 Time: 5:30 PM - 7:30 PM ET Room: OCCC - West Halls B3-B4 Publication Number: 1290 Quality of life and functional improvements with Efanesoctocog alfa in patients with moderate to severe Haemophilia A: A real-world survey. Poster Presentation Session name: Poster Session III Date: 8 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Publication Number: 4846 Pegcetacoplan Consistent benefits of Pegcetacoplan treatment in PNH patients with and without a history of Aplastic Anaemia in real world: Analysis of the ongoing COMPLETE Phase 4 observational study. Poster Presentation Session Name: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster I Date: 6 December 2025 Time: 5:30 PM - 7:30 PM ET Room: OCCC - West Halls B3-B4 Early results from the ongoing Pegcetacoplan Silo of the International Paroxysmal Nocturnal Haemoglobinuria Interest Group Registry. Poster Presentation Session Name: 508. Bone Marrow Failure: Acquired: Poster II Date: 7 December 2025 Time: 6:00:00 PM – 6:00:00 PM ET Location: OCCC - West Halls B3-B4 Real-world clinical characteristics and treatment outcomes in PNH patients prescribed Pegcetacoplan: Insights of complement inhibitor-experienced and -naïve patients across Europe, the United States and Canada. Poster Presentation Session Name: 508. Bone Marrow Failure: Acquired: Poster III Date: 8 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Pegcetacoplan - Publication Only Abstracts Real-world effectiveness of Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria: A systematic review of clinical and patient-reported outcomes. Publication only - published online on 3 November 2025, at 9:00 AM ET Low risk for Meningococcal and encapsulated bacteria infections with systemically administered Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria and C3 Glomerulopathies. Overview of treatment advances with complement Inhibitors in patients with Paroxysmal Nocturnal Haemoglobinuria. Optimising PNH treatment with the complement inhibitor Pegcetacoplan: A case report. User experience with Pegcetacoplan on-body Injector in patients with Paroxysmal Nocturnal Hemoglobinuria. Avatrombopag Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from Eltrombopag or Romiplostim to Avatrombopag in the United States: Results from the real-AVA 3.5 study. Poster Presentation Session Name: 905. Outcomes research: Non-malignant conditions excluding Hemoglobinopathies: Poster I Date: 6 December 2025 Time: 5:30 PM - 7:30 PM ET Room: OCCC - West Halls B3-B4 Real-world safety and efficacy of Avatrombopag in adults with Immune Thrombocytopenia: A systematic review and meta-analysis. Global Abstract Session Name: 311. Disorders of platelet number or function: Clinical and epidemiological: Poster I Date: 6 December 2025 Time: 5:30 PM – 7:30 PM ET Room: OCCC – West Halls B3-B4 Patient-reported outcomes of Avatrombopag for Chronic Immune Thrombocytopenia: Interim analysis of the Phase 4 ADOPT Study. Poster Presentation Session Name: 905. Outcomes research: Non-malignant conditions excluding Hemoglobinopathies: Poster III Date: 8 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Emapalumab Use of Emapalumab is associated with rapid and sustained benefits in pHLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-050105 and NI-050109. Poster Presentation Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster II Date: 7 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09. Poster Presentation Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster III Date: 8 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Pacritinib Real-world treatment patterns and outcomes in patients with myelofibrosis who presented with thrombocytopenia and anaemia at initiation of Pacritinib treatment. Oral Presentation Session Name: 908. Outcomes Research: Myeloid Malignancies: Real-World Experiences Session date: 7 December 2025 Session time: 4:30 PM - 6:00 PM ET Presentation time: 5:30 PM - 5:45 PM Room: OCCC - W414CD Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies. Poster Presentation Session Name: 634. Myeloproliferative Syndromes: Clinical and epidemiological: Poster I Date: 6 December 2025 Time: 5:30 PM - 7:30 PM ET Room: OCCC - West Halls B3-B4 Real-world treatment patterns and clinical outcomes in patients with Myelofibrosis treated with Pacritinib (PAC): Results from the MY-PAC Study. Poster Presentation Session Name: 908. Outcomes research: Myeloid Malignancies: Poster II Date: 7 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 PROSPERA (ABNL-MARRO 002): A randomised Phase 2 study of Pacritinib vs. Hydroxyurea in patients with Advanced Proliferative Chronic Myelomonocytic Leukaemia (CMML) Poster Presentation Session Name: 637. Myelodysplastic Syndromes: Clinical and epidemiological: Poster II Date: 7 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Treatment patterns and outcomes in patients with myelofibrosis treated with Pacritinib following a switch from Ruxolitinib: The MY-PAC Study. Session Name: 634. Myeloproliferative Syndromes: Clinical and epidemiological: Poster III Date: 8 December 2025 Time: 6:00 PM - 8:00 PM ET Room: OCCC - West Halls B3-B4 Incidence, prevalence, and clinical outcomes of Myelofibrosis with and without Cytopenia in the United States. About ALTUVOCT ® (efanesoctocog alfa) ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity. About the Sobi and Sanofi Collaboration Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Aspaveli®/Empaveli® (pegcetacoplan) Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the United States. It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally. About the Sobi and Apellis Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Doptelet® (avatrombopag) Doptelet (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. Doptelet is also approved for the treatment of chronic ITP in pediatric patients. About Gamifant® (emapalumab-lzsg) Gamifant is an anti-IFNγ antibody that binds free and receptor-bound IFNγ, which when secreted in an uncontrolled manner can cause hyperinflammation. Gamifant is indicated for intravenous infusion over one hour and is FDA approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) in Still’s disease. About Vonjo® (pacritinib) Vonjo (pacritinib) is a kinase inhibitor indicated in the United States for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Vonjo is also being investigated for other rare hematologic conditions, including VEXAS syndrome. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. To stay up to date with our development, please subscribe to our press releases. Sign up We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. At a glance Focus on rare diseases Business strategy Partnership Partnership Our commitment Connect Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Nurture Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Collaborate Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Innovate Innovate disease awareness campaigns Value added services Connect Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Nurture Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Collaborate Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Innovate Innovate disease awareness campaigns Value added services Innovate disease awareness campaigns Value added services History Board of directors Executive committee Corporate Governance General Meetings Nomination committee Committees Remuneration Auditors Articles of association General Meetings Nomination committee Committees Remuneration Auditors Articles of association Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care. Haematology Haemophilia Immune thrombocytopenia (ITP) Paroxysmal nocturnal haemoglobinuria (PNH) Diffuse large B-cell lymphoma (DLBCL) Haemophilia Immune thrombocytopenia (ITP) Paroxysmal nocturnal haemoglobinuria (PNH) Diffuse large B-cell lymphoma (DLBCL) Immunology Familial Mediterranean fever (FMF) Cryopyrin-associated periodic syndromes (CAPS) Haemophagocytic lymphohistiocytosis (HLH) Respiratory syncytial virus (RSV) Still’s disease Familial Mediterranean fever (FMF) Cryopyrin-associated periodic syndromes (CAPS) Haemophagocytic lymphohistiocytosis (HLH) Respiratory syncytial virus (RSV) Still’s disease Specialty Care Pipeline Congresses Research & development Investigator sponsored studies Managed Access Programmes Clinical studies and data privacy Investigator sponsored studies Managed Access Programmes Clinical studies and data privacy Medical Grant We contribute to societies by improving access to treatment of rare diseases. Sustainability performance Key data Key data Sustainability governance Code of Conduct Policies Governance Code of Conduct Policies Governance Commitment to patients Access to treatment Patient centricity Humanitarian aid Access to treatment Patient centricity Humanitarian aid Act responsibly Caring for employees Environmental footprint Responsible sourcing Compliance Caring for employees Environmental footprint Responsible sourcing Compliance Transparency Disclosure of Payments to Healthcare Trade association memberships Supporting patient organisations Disclosure of Payments to Healthcare Trade association memberships Supporting patient organisations Find out more about our business and financial performance. Financial reports Presentations Financial data Calendar Pipeline Share information All trading venues Historical share price look-up Ownership Analyst coverage All trading venues Historical share price look-up Ownership Analyst coverage IR contacts Subscribe MTN-programme Rights issue 2023 Here we present our most recent press releases, stories, news articles, and images. Press releases News Image gallery YouTube Subscribe Every day, we work actively to find better ways to understand and meet patient needs. Our values Meet our employees Open positions About At a glance Focus on rare diseases Business strategy Partnership Our commitment Connect Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Nurture Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Collaborate Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Innovate Innovate disease awareness campaigns Value added services History Board of directors Executive committee Corporate Governance General Meetings Nomination committee Committees Remuneration Auditors Articles of association Therapeutic areas Haematology Haemophilia Immune thrombocytopenia (ITP) Paroxysmal nocturnal haemoglobinuria (PNH) Diffuse large B-cell lymphoma (DLBCL) Immunology Familial Mediterranean fever (FMF) Cryopyrin-associated periodic syndromes (CAPS) Haemophagocytic lymphohistiocytosis (HLH) Respiratory syncytial virus (RSV) Still’s disease Specialty Care Pipeline Congresses Research & development Investigator sponsored studies Managed Access Programmes Clinical studies and data privacy Medical Grant Medicines Stories Sustainability Sustainability performance Key data Sustainability governance Code of Conduct Policies Governance Commitment to patients Access to treatment Patient centricity Humanitarian aid Act responsibly Caring for employees Environmental footprint Responsible sourcing Compliance Transparency Disclosure of Payments to Healthcare Trade association memberships Supporting patient organisations Investors Financial reports Presentations Financial data Calendar Pipeline Share information All trading venues Historical share price look-up Ownership Analyst coverage IR contacts Subscribe MTN-programme Rights issue 2023 News Press releases News Image gallery YouTube Subscribe Careers Our values Meet our employees Open positions At a glance Focus on rare diseases Business strategy Partnership Our commitment Connect Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Nurture Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Collaborate Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Innovate Innovate disease awareness campaigns Value added services History Board of directors Executive committee Corporate Governance General Meetings Nomination committee Committees Remuneration Auditors Articles of association Partnership Connect Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Nurture Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Collaborate Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Innovate Innovate disease awareness campaigns Value added services Disease awareness Patients as equal contributors Access programmes Clinical Trials Humanitarian programmes Capability building Trusted education source Patient Engagement in acquisitions Continuous and transparent communication Define and deliver on shared objectives Informed decision making (IDM) Patient Engagement and experience data Innovate disease awareness campaigns Value added services General Meetings Nomination committee Committees Remuneration Auditors Articles of association Haematology Haemophilia Immune thrombocytopenia (ITP) Paroxysmal nocturnal haemoglobinuria (PNH) Diffuse large B-cell lymphoma (DLBCL) Immunology Familial Mediterranean fever (FMF) Cryopyrin-associated periodic syndromes (CAPS) Haemophagocytic lymphohistiocytosis (HLH) Respiratory syncytial virus (RSV) Still’s disease Specialty Care Pipeline Congresses Research & development Investigator sponsored studies Managed Access Programmes Clinical studies and data privacy Medical Grant Haemophilia Immune thrombocytopenia (ITP) Paroxysmal nocturnal haemoglobinuria (PNH) Diffuse large B-cell lymphoma (DLBCL) Familial Mediterranean fever (FMF) Cryopyrin-associated periodic syndromes (CAPS) Haemophagocytic lymphohistiocytosis (HLH) Respiratory syncytial virus (RSV) Still’s disease Investigator sponsored studies Managed Access Programmes Clinical studies and data privacy Sustainability performance Key data Sustainability governance Code of Conduct Policies Governance Commitment to patients Access to treatment Patient centricity Humanitarian aid Act responsibly Caring for employees Environmental footprint Responsible sourcing Compliance Transparency Disclosure of Payments to Healthcare Trade association memberships Supporting patient organisations Key data Code of Conduct Policies Governance Access to treatment Patient centricity Humanitarian aid Caring for employees Environmental footprint Responsible sourcing Compliance Disclosure of Payments to Healthcare Trade association memberships Supporting patient organisations Financial reports Presentations Financial data Calendar Pipeline Share information All trading venues Historical share price look-up Ownership Analyst coverage IR contacts Subscribe MTN-programme Rights issue 2023 All trading venues Historical share price look-up Ownership Analyst coverage Press releases News Image gallery YouTube Subscribe Our values Meet our employees Open positions